SC
REGN icon

Syon Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Syon Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$789K Buy
1,021
+83
+9% +$63.5K 0.04% 385
2025
Q4 		$724K Buy
938
+148
+19% +$101K 0.04% 414
2025
Q3 		$444K Sell
790
-85
-10% -$48.1K 0.02% 532
2025
Q2 		$459K Sell
875
-570
-39% -$318K 0.03% 404
2025
Q1 		$916K Buy
1,445
+162
+13% +$111K 0.07% 194
2024
Q4 		$914K Buy
1,283
+389
+44% +$326K 0.08% 174
2024
Q3 		$940K Sell
894
-8
-0.9% -$8.9K 0.08% 175
2024
Q2 		$948K Buy
902
+13
+1% +$12.6K 0.09% 162
2024
Q1 		$856K Sell
889
-675
-43% -$642K 0.08% 184
2023
Q4 		$1.37M Buy
1,564
+950
+155% +$782K 0.06% 198
2023
Q3 		$505K Buy
+614
New +$483K 0.06% 181

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Syon Capital's REGN Position: Q1 2026 in Review

Syon Capital increased its Regeneron Pharmaceuticals (REGN) stake by 8.8% in Q1 2026, buying an estimated $63.5K and bringing the position to 1,021 shares worth $789K. The position accounts for 0.04% of the portfolio, ranked #385.

Syon Capital first reported a position in REGN in Q3 2023 and has held it in 11 quarters since. The position peaked at $1.37M in Q4 2023. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Syon Capital held 1,021 shares of Regeneron Pharmaceuticals worth $789K as of Q1 2026.
  • Syon Capital bought 83 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $63.5K.
  • Regeneron Pharmaceuticals made up 0.04% of Syon Capital's portfolio in Q1 2026, its #385 holding.
  • Syon Capital first reported a position in Regeneron Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
  • Syon Capital's Regeneron Pharmaceuticals position peaked at $1.37M in Q4 2023.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Syon Capital's 13F filing for Q1 2026, filed 13 May 2026.